免疫療法関連の事業提携 (2014～2020年)：取引動向、企業、財務情報

当レポートでは、免疫療法の治療薬開発に関する昨今 (2014～2020年) の提携取引の動向について分析し、全体的な取引形成件数の推移や、財務面 (支払条件) での傾向、主要企業 (全25社) による取引形成の動き、契約条件の傾向、適応症別 (治療標的別) の傾向などを調査すると共に、近年の主要な提携取引 (全700件以上) の詳細情報を取りまとめてお届けいたします。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 免疫療法関連の取引形成の傾向

• イントロダクション
• 免疫療法関連の取引形成：近年の動向
• 免疫療法関連の取引形成：取引の種類別
• 免疫療法関連の取引形成：業界別
• 免疫療法関連の取引形成：開発段階別
• 免疫療法関連の取引形成：技術の種類別
• 免疫療法関連の取引形成：適応症別

第3章 免疫療法関連の事業提携：財務面での条件

• イントロダクション
• 免疫療法関連の事業提携の開示されている財政的条件
• 免疫療法関連の事業提携：取引総額
• 免疫療法関連の事業提携：前払い金
• 免疫療法関連の事業提携：マイルストーン払い
• 免疫療法関連の事業提携：ロイヤルティ率

第4章 免疫療法関連の代表的な取引

• イントロダクション
• 免疫療法関連の提携で最も活動的な企業
• 免疫療法の分野で最も活動的な企業：提携取引の一覧
• 免疫療法関連の主要な取引：契約金額別

第5章 免疫療法の契約文書ディレクトリ

• イントロダクション
• 免疫療法関連の資本取引の動向：契約文章が閲覧可能な取引の場合

第6章 免疫療法関連の取引形成：治療標的別

• イントロダクション
• 免疫療法関連の取引形成：治療標的別

付録

• 付録 (1)：免疫療法関連の提携取引一覧、企業名別 (2014～2020年)
• 付録 (2)：免疫療法関連の提携取引一覧、取引の種類別 (2014～2020年)
• 付録 (3)：免疫療法関連の提携取引一覧、開発段階別 (2014～2020年)
• 付録 (4)：免疫療法関連の提携取引一覧、技術の種類別 (2014～2020年)

The Global Immunology Partnering 2014-2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the Immunology partnering deals and agreements entered into by the worlds leading healthcare companies

Global Immunology Partnering 2014 to 2020 provides the full collection of Immunology disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.

Trends in Immunology partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Immunology partnering agreement structure

Immunology partnering contract documents

Top Immunology deals by value

Most active Immunology dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Immunology deals.

The report presents financial deal terms values for Immunology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Immunology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Immunology dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Immunology deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Immunology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Immunology deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Immunology partnering deals by specific Immunology target announced since 2014. The chapter is organized by specific Immunology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Immunology partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Immunology partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Immunology technologies and products.

Report scope

Global Immunology Partnering 2014 to 2020 is intended to provide the reader with an in-depth understanding and access to Immunology trends and structure of deals entered into by leading companies worldwide.

Global Immunology Partnering 2014 to 2020 includes:

• Trends in Immunology dealmaking in the biopharma industry since 2014
• Analysis of Immunology deal structure
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of Immunology deal contract documents
• Comprehensive access to over 780 Immunology deal records
• The leading Immunology deals by value since 2014
• Most active Immunology dealmakers since 2014
• The report includes deals for the following indications: AIDS, Allergy, Anaphylactic shock, Graft versus host disease, Inflammation, Other autoimmune, Scleroderma, Systemic lupus erythematosus, plus other immunology indications.

In Global Immunology Partnering 2014 to 2020, available deals and contracts are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Stage of development at signing
• Deal component type
• Technology type
• Specific therapy indication
• Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Immunology Partnering 2014-2020 report provides comprehensive access to available deals and contract documents for over 780 immunology deals. Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are the sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Immunology Partnering 2014 to 2020 provides the reader with the following key benefits:

• In-depth understanding of Immunology deal trends since 2014
• Access Immunology deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between Immunology partner companies
• Comprehensive access to over 780 links to actual Immunology deals entered into by the world's biopharma companies
• Indepth review of Immunology deals entered into by the top 25 most active dealmakers
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner Immunology opportunities
• Uncover companies actively partnering Immunology opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Immunology dealmaking

• 2.1. Introduction
• 2.2. Immunology partnering over the years
• 2.3. Immunology partnering by deal type
• 2.4. Immunology partnering by industry sector
• 2.5. Immunology partnering by stage of development
• 2.6. Immunology partnering by technology type
• 2.7. Immunology partnering by therapeutic indication

Chapter 3 -Financial deal terms for Immunology partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for Immunology partnering
• 3.3. Immunology partnering headline values
• 3.4. Immunology deal upfront payments
• 3.5. Immunology deal milestone payments
• 3.6. Immunology royalty rates

Chapter 4 - Leading Immunology deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in Immunology partnering
• 4.3. List of most active dealmakers in Immunology
• 4.4. Top Immunology deals by value

Chapter 5 - Immunology contract document directory

• 5.1. Introduction
• 5.2. Immunology partnering deals where contract document available

Chapter 6 - Immunology dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by Immunology therapeutic target

Appendices

• Appendix 1 - Directory of Immunology deals by company A-Z 2014 to 2020
• Appendix 2 - Directory of Immunology deals by deal type 2014 to 2020
• Appendix 3 - Directory of Immunology deals by stage of development 2014 to 2020
• Appendix 4 - Directory of Immunology deals by technology type 2014 to 2020
• Further reading on dealmaking
• Deal type definitions
• About Wildwood Ventures
• Current Partnering
• Current Agreements
• Recent report titles from CurrentPartnering
• Table of figures
• Figure 1: Immunology partnering since 2014
• Figure 2: Immunology partnering by deal type since 2014
• Figure 3: Immunology partnering by industry sector since 2014
• Figure 4: Immunology partnering by stage of development since 2014
• Figure 5: Immunology partnering by technology type since 2014
• Figure 6: Immunology partnering by indication since 2014
• Figure 7: Immunology deals with a headline value
• Figure 8: Immunology deals with upfront payment values
• Figure 9: Immunology deals with milestone payment
• Figure 10: Immunology deals with royalty rates
• Figure 11: Active Immunology dealmaking activity- 2014 to 2020
• Figure 12: Top Immunology deals by value since 2014